3',4'-AnhydrovinblastineCAS# 38390-45-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 38390-45-3 | SDF | Download SDF |
| PubChem ID | 443324 | Appearance | Powder |
| Formula | C46H56N4O8 | M.Wt | 792.96 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CCC1=CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC | ||
| Standard InChIKey | FFRFGVHNKJYNOV-DOVUUNBWSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. 3',4'-Anhydrovinblastine is an antineoplastic agent. |
3',4'-Anhydrovinblastine Dilution Calculator
3',4'-Anhydrovinblastine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.2611 mL | 6.3055 mL | 12.611 mL | 25.222 mL | 31.5274 mL |
| 5 mM | 0.2522 mL | 1.2611 mL | 2.5222 mL | 5.0444 mL | 6.3055 mL |
| 10 mM | 0.1261 mL | 0.6305 mL | 1.2611 mL | 2.5222 mL | 3.1527 mL |
| 50 mM | 0.0252 mL | 0.1261 mL | 0.2522 mL | 0.5044 mL | 0.6305 mL |
| 100 mM | 0.0126 mL | 0.0631 mL | 0.1261 mL | 0.2522 mL | 0.3153 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Taxinine
Catalog No.:BCN6944
CAS No.:3835-52-7
- Neuropeptide W-23 (human)
Catalog No.:BCC5961
CAS No.:383415-79-0
- UC 112
Catalog No.:BCC8042
CAS No.:383392-66-3
- Homovanillic Acid Sulfate
Catalog No.:BCN2226
CAS No.:38339-06-9
- 3-O-beta-D-Glucopyranosylplatycodigenin
Catalog No.:BCN7832
CAS No.:38337-25-6
- YE 120
Catalog No.:BCC6188
CAS No.:383124-82-1
- Minoxidil
Catalog No.:BCC4297
CAS No.:38304-91-5
- Naringenin trimethyl ether
Catalog No.:BCN5437
CAS No.:38302-15-7
- Burchellin
Catalog No.:BCN6676
CAS No.:38276-59-4
- Glucose-conjugated MGMT inhibitor
Catalog No.:BCC1597
CAS No.:382607-78-5
- Malonomicin
Catalog No.:BCN1844
CAS No.:38249-71-7
- 20(R)-Ginsenoside Rg3
Catalog No.:BCN5018
CAS No.:38243-03-7
- NSC 663284
Catalog No.:BCC7199
CAS No.:383907-43-5
- Caudatin
Catalog No.:BCN5810
CAS No.:38395-02-7
- Ganaxolone
Catalog No.:BCC7397
CAS No.:38398-32-2
- Aloenin
Catalog No.:BCN8438
CAS No.:38412-46-3
- Altechromone A
Catalog No.:BCN7422
CAS No.:38412-47-4
- 3,4,4',7-Tetrahydroxyflavan
Catalog No.:BCN5438
CAS No.:38412-82-7
- Sclareol glycol
Catalog No.:BCN7007
CAS No.:38419-75-9
- H-Lys-OEt .2HCl
Catalog No.:BCC2980
CAS No.:3844-53-9
- Asatone
Catalog No.:BCN7761
CAS No.:38451-63-7
- Deacetyleupaserrin
Catalog No.:BCN7228
CAS No.:38456-39-2
- Eucannabinolide
Catalog No.:BCN7221
CAS No.:38458-58-1
- Crotafoline
Catalog No.:BCN2075
CAS No.:38494-87-0
The coupling of catharanthine and vindoline to form 3',4'-anhydrovinblastine by haemoproteins and haemin.[Pubmed:17265256]
Planta Med. 1988 Jun;54(3):210-4.
The enzymic coupling of catharanthine and vindoline can be performed with plant peroxidases in a reaction which yields 3',4'-anhydrovinblastine (AVLB) as the major product. This has led to an investigation of other sources of peroxidase activity and haem. High levels of AVLB were obtained using microperoxidase (haem-undecapeptide) and haemin, and lower yields were also detected with lactoperoxidase, cytochrome C, and haemoglobin. The activity with haemin and microperoxidase has been optimized and it is concluded that, in comparison with horseradish peroxidase, these systems provide an improved means of coupling.
Production and metabolic engineering of terpenoid indole alkaloids in cell cultures of the medicinal plant Catharanthus roseus (L.) G. Don (Madagascar periwinkle).[Pubmed:19281450]
Biotechnol Appl Biochem. 2009 Apr;52(Pt 4):313-23.
The Madagascar periwinkle [Catharanthus roseus (L.) G. Don] is a plant species known for its production of TIAs (terpenoid indole alkaloids), many of which are pharmaceutically important. Ajmalicine and serpentine are prescribed for the treatment of hypertension, whereas the bisindoles vinblastine, vincristine and 3',4'-anhydrovinblastine are used for their antineoplastic activity in the treatment of many cancers. However, TIAs are produced in small yields in C. roseus, which make them expensive. Cell and metabolic engineering has focused on increasing flux through the TIA pathway by various means, including optimization of medium composition, elicitation, construction of noval culture systems and introduction of genes encoding specific metabolic enzymes into the C. roseus genome. The present review will attempt to present the state-of-the-art of research in this area and provide an update on the cell and metabolic engineering of TIAs in C. roseus. We hope that this will contribute to a better understanding of the ways in which TIA production can be achieved in different C. roseus culture systems.
